CompletedPhase 2

Effect of Finerenone in Patients With Non-diabetic Glomerulonephritis

Egypt100 participantsStarted 2025-04-01

Plain-language summary

This study aims to assess the effect of finerenone on proteinuria and GFR progression in patients with non-diabetic glomerulonephritis.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. GN patients on maximum tolerated doses of an ACEi or ARBs together with their immunosuppression protocol (if needed) for at least 4 weeks.
. urinary protein excretion \>500 mg/g.
. Adult patients with age above 18 years.
. eGFR ≥ 25 mL/ min/1.73 m2.
. baseline serum potassium level \<5 mEq/L.

Exclusion criteria

. Patients with diabetes mellitus (type 1 or 2).
. Other non-glomerular kidney diseases.
. Heart failure.
. Breast feeding or pregnancy.
. Patients who received medications to treat hyperkalemia 4 weeks before study.
. Uncontrolled hypertension (BP \> 160/100).

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

- Change in kidney function

Timeframe: 9 months

- Change in proteinuria

Timeframe: 9 months

Change in kidney function

Timeframe: 9 months

Trial details

NCT IDNCT06835322

SponsorAlexandria University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-03-01

View on ClinicalTrials.gov More Glomerulonephritis trials

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. GN patients on maximum tolerated doses of an ACEi or ARBs together with their immunosuppression protocol (if needed) for at least 4 weeks.
. urinary protein excretion \>500 mg/g.
. Adult patients with age above 18 years.
. eGFR ≥ 25 mL/ min/1.73 m2.
. baseline serum potassium level \<5 mEq/L.

Exclusion criteria

. Patients with diabetes mellitus (type 1 or 2).
. Other non-glomerular kidney diseases.
. Heart failure.
. Breast feeding or pregnancy.
. Patients who received medications to treat hyperkalemia 4 weeks before study.
. Uncontrolled hypertension (BP \> 160/100).